Table 1.
Patient characteristics of the study population
| Clinical characteristics | N = 68 |
|---|---|
| Age (years) | 69 ± 8 |
| Male | 52 (76) |
| Blood pressure | |
| Systolic (mmHg) | 137 ± 18 |
| Diastolic (mmHg) | 72 ± 11 |
| Body mass index (kg/m2) | 31.2 ± 5.3 |
| Smokers | |
| Former | 42 (62) |
| Current | 10 (15) |
| Femoral 18F-NaF PET TBR | 2.2 ± 0.7 |
| Femoral calcium mass by CT | 118 (14–451) |
| Cholesterol | |
| Total (mmol/l) | 4.4 [3.5–5] |
| LDL (mmol/l) | 2.1 [1.4–2.5] |
| HDL(mmol/l) | 1.1 ± 0.3 |
| Triglycerides (mmol/l) | 2.9 [1.6–3.4] |
| HbA1c (mmol/mol) | 58.2 [47.3–63.0] |
| Serum creatine (μmol/l) | 85.2 ± 23.4 |
| History of arterial disease | |
| CAD | 41 (60) |
| CVA, TIA | 23 (34) |
| PAD | 16 (24) |
| ABI < 0.9 | 18 (27) |
| AAA | 6 (9) |
| Medication use | |
| Insulin | 32 (47) |
| Glucose lowering drugs | 60 (88) |
| Statins | 52 (77) |
| Lipid lowering drugs | 31 (46) |
| Bisphosphonates | 1 (2) |
| Antihypertensive drugs | 60 (88) |
| Platelet inhibitors | 31 (46) |
| Calcium supplements | 9 (13) |
| Vitamin D supplements | 21 (31) |
Values are represented as mean ± SD, median [Q1-Q3] or n (%)
TBR, target-to-background ratio; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin; CAD, coronary artery disease; CVA, TIA, cerebrovascular disease, transient ischemic attack; PAD, peripheral artery disease; ABI < 0.9, ankle brachial index < 0.9; AAA, abdominal aortic aneurysm